{
  "0": "Two interventional studies for relapsing-remitting multiple sclerosis involving Cladribine 5.25 mg/kg were started in April 2005:\n\n1. [NCT00213135](https://clinicaltrials.gov/ct2/show/NCT00213135)\n2. [NCT00641537](https://clinicaltrials.gov/ct2/show/NCT00641537)",
  "1": "Here are the completed interventional studies for gout with the main interventions pegloticase or placebo that started in May 2006 in the United States:\n\n1. **NCT03994731**\n2. **NCT03303989**\n3. **NCT00325195**\n4. **NCT01356498**\n\nThese studies are registered in ClinicalTrials.gov, and you can find more details by searching these NCT IDs on the ClinicalTrials.gov website.",
  "2": "The PMID of the 2025 BMC Pulmonary Medicine article titled \"Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC,\" with Wang X as the first author, is 40483449.",
  "3": "I couldn't find any article matching the title \"Trends in self-citation rates in high-impact neurology, neuroscience, and psychiatry journals\" authored by Rosenblatt M in the journal eLife published in 2025. It's possible that the article isn't indexed in PubMed or may not have been published yet. If you have any other details or requests, feel free to let me know.",
  "4": "The tractability information for the target with Ensembl ID ENSG00000140443 and approved symbol IGF1R, where the value is True, includes the following modalities:\n\n### Small Molecule (SM)\n- **Approved Drug**\n- **Structure with Ligand**\n- **High-Quality Ligand**\n- **High-Quality Pocket**\n- **Druggable Family**\n\n### Antibody (AB)\n- **Approved Drug**\n- **UniProt loc high conf**\n- **GO CC high conf**\n- **UniProt SigP or TMHMM**\n\n### Proteolysis Targeting Chimera (PR)\n- **Literature**\n- **UniProt Ubiquitination**\n- **Database Ubiquitination**\n- **Half-life Data**\n- **Small Molecule Binder**\n\n### Occupational Category (OC)\n- **Approved Drug**\n\nThese modalities collectively indicate the different levels at which the target IGF1R is considered tractable for drug development and therapeutic intervention.",
  "5": "The unique PMID of the article titled “Next-generation sequencing and immuno-informatics for designing a multi-epitope vaccine against HSV-1-induced uveitis,” authored by Cao H and published in Frontiers in Immunology in 2025 is 39958333.",
  "6": "The target ERBB2 (Ensembl ID ENSG00000141736) is associated with the following diseases in OpenTargets with a minimum relevance score of 0.5:\n\n1. **Non-Small Cell Lung Carcinoma** - Score: 0.7568\n2. **Cancer** - Score: 0.7317\n3. **Breast Carcinoma** - Score: 0.6987\n4. **Neoplasm** - Score: 0.6755\n5. **Gastric Cancer** - Score: 0.6656\n6. **Breast Adenocarcinoma** - Score: 0.6357\n7. **Breast Cancer** - Score: 0.6337\n8. **Lung Adenocarcinoma** - Score: 0.6249\n9. **Urinary Bladder Carcinoma** - Score: 0.6108\n10. **Breast Neoplasm** - Score: 0.6107\n11. **Lung Cancer** - Score: 0.6000\n12. **HER2 Positive Breast Carcinoma** - Score: 0.5834\n13. **Gastric Adenocarcinoma** - Score: 0.5646\n14. **Glomerular Filtration Rate** - Score: 0.5565\n15. **Urinary Bladder Cancer** - Score: 0.5400\n16. **Ovarian Cancer** - Score: 0.5318\n\nThese are the diseases linked to ERBB2, along with their respective relevance scores.",
  "7": "The PMID of the article titled \"Diversity is essential in cardiovascular medicine and subspecialties: A comprehensive report of gender, racial, and ethnic representation among cardiovascular fellows from 2005 to 2022,\" authored by Obeidat O and published in Current Problems in Cardiology in 2025, is 40311855.",
  "8": "For the target with Ensembl ID ENSG00000239732 and approved symbol TLR9, the following tractability modalities are available with the value set to True:\n\n- **Small Molecule (SM)**\n  - Approved Drug\n  - High-Quality Ligand\n  - Druggable Family\n\n- **Antibody (AB)**\n  - GO Cellular Component (CC) high confidence\n  - UniProt Signal Peptide or Transmembrane Helix Model (TMHMM)\n\n- **PROTAC/Degrader (PR)**\n  - Database Ubiquitination\n  - Small Molecule Binder\n\n- **Other Clinical (OC)**\n  - Advanced Clinical",
  "9": "The target VEGFA (Ensembl ID: ENSG00000112715) is associated with the following diseases with a minimum relevance score of 0.5 in OpenTargets:\n\n1. **Diabetic Retinopathy** - Score: 0.6932\n2. **Age-related Macular Degeneration** - Score: 0.6666\n3. **Wet Macular Degeneration** - Score: 0.6476\n4. **Macular Retinal Edema** - Score: 0.6098\n5. **Non-small Cell Lung Carcinoma** - Score: 0.6088\n6. **Breast Cancer** - Score: 0.6060\n7. **Glioblastoma Multiforme** - Score: 0.5982\n8. **Neoplasm** - Score: 0.5862\n9. **Ovarian Cancer** - Score: 0.5800\n10. **Renal Cell Carcinoma** - Score: 0.5694\n11. **Macular Degeneration** - Score: 0.5555\n12. **Ocular Vascular Disease** - Score: 0.5535\n13. **Hematocrit** - Score: 0.5529\n14. **Colorectal Neoplasm** - Score: 0.5479\n15. **Hemoglobin Measurement** - Score: 0.5449\n16. **Colorectal Adenocarcinoma** - Score: 0.5374\n17. **Erythrocyte Count** - Score: 0.5349\n18. **Cervical Cancer** - Score: 0.5261\n19. **Neutrophil Count** - Score: 0.5169\n20. **Platelet Count** - Score: 0.5162\n21. **Leukocyte Count** - Score: 0.5156\n22. **HbA1c Measurement** - Score: 0.5080\n23. **Ovarian Carcinoma** - Score: 0.5049\n24. **Macrovascular Complications of Diabetes** - Score: 0.5030\n\nThese associations indicate varying degrees of relevance between the target and different diseases, with diabetic retinopathy showing the highest relevance score.",
  "10": "It seems there isn't any article matching your search criteria available in PubMed. It's possible that the article has not been indexed yet, or there might be incorrect details in the search query. Please ensure the title, author, and publication details are correct and try again later.",
  "11": "The unique PMID for the article titled “On tending sprouts: empowering emerging immunologists in Latin America,” authored by Brunck MEG and published in Trends in Immunology in 2025, is 40050163.",
  "12": "I couldn't find any articles matching the title and criteria you provided in the PubMed database. It's possible that the article is not yet indexed or the details may need to be verified. Please ensure the publication details are correct, or check back later if the article is new.",
  "13": "The PMID for the article titled \"[Exploring screening practices for sexual disorders in breast cancer patients],\" authored by Jacquet C and published in Soins; la revue de reference infirmiere in 2025, is 40483090.",
  "14": "There are no recruiting interventional studies investigating Bexmarilimab in Finland that started in June 2022 according to ClinicalTrials.gov.",
  "15": "The unique PMID for the 2025 BMJ Open Quality article titled “Clinical impact of Choosing Wisely Canada hepatology recommendations: an interrupted time-series analysis using data from GEMINI,” authored by Shin S is 40122575.",
  "16": "The completed interventional studies for relapsing-remitting multiple sclerosis involving Fingolimod 1.25 mg, Fingolimod 0.5 mg, or Placebo that started in January 2006 in Australia are:\n\n1. NCT00355134\n2. NCT00340834\n3. NCT00662649\n4. NCT00289978\n\nThese are the NCT IDs of the studies.",
  "17": "The following are completed interventional studies conducted in the United States for metastatic breast cancer with Eribulin Mesylate as a main intervention:\n\n1. NCT01269346\n2. NCT02915744\n3. NCT01492101\n4. NCT01908101\n5. NCT02120469\n6. NCT03262935\n7. NCT03901339\n8. NCT01795586\n9. NCT02513472\n10. NCT02581839\n11. NCT01268150\n12. NCT01837095\n13. NCT02574455\n14. NCT03430518\n15. NCT02481050\n16. NCT01945775\n17. NCT01827787\n18. NCT01802970\n19. NCT01401959\n20. NCT03051659\n21. NCT00337103\n22. NCT02014337\n23. NCT02492711\n24. NCT01554371\n25. NCT01427933\n26. NCT01596751\n27. NCT01156753\n\nYou can search these NCT IDs on ClinicalTrials.gov for more detailed information on each study.",
  "18": "The PMID of the article titled \"HeartConnect: Integrating primary care and specialist cardiology for rapid access and better patient and healthcare practitioner experiences,\" with the first author Zurynski Y, published in the Australian Journal of General Practice, is 40320805.",
  "19": "Here are the completed interventional studies for Non-Hodgkins Lymphoma involving Lenalidomide that started in August 2005 in the United States:\n\n1. [NCT01996865](https://clinicaltrials.gov/ct2/show/NCT01996865)\n2. [NCT00784927](https://clinicaltrials.gov/ct2/show/NCT00784927)\n3. [NCT01197560](https://clinicaltrials.gov/ct2/show/NCT01197560)\n4. [NCT01995669](https://clinicaltrials.gov/ct2/show/NCT01995669)\n5. [NCT01938001](https://clinicaltrials.gov/ct2/show/NCT01938001)\n6. [NCT00179660](https://clinicaltrials.gov/ct2/show/NCT00179660)\n7. [NCT01088048](https://clinicaltrials.gov/ct2/show/NCT01088048)\n8. [NCT00783367](https://clinicaltrials.gov/ct2/show/NCT00783367)\n9. [NCT03019640](https://clinicaltrials.gov/ct2/show/NCT03019640)\n10. [NCT01035463](https://clinicaltrials.gov/ct2/show/NCT01035463)\n11. [NCT00695786](https://clinicaltrials.gov/ct2/show/NCT00695786)\n12. [NCT01429025](https://clinicaltrials.gov/ct2/show/NCT01429025)\n13. [NCT02561273](https://clinicaltrials.gov/ct2/show/NCT02561273)\n14. [NCT00737529](https://clinicaltrials.gov/ct2/show/NCT00737529)\n15. [NCT01316523](https://clinicaltrials.gov/ct2/show/NCT01316523)\n16. [NCT01145495](https://clinicaltrials.gov/ct2/show/NCT01145495)\n17. [NCT00238238](https://clinicaltrials.gov/ct2/show/NCT00238238)\n18. [NCT01755975](https://clinicaltrials.gov/ct2/show/NCT01755975)\n19. [NCT01075321](https://clinicaltrials.gov/ct2/show/NCT01075321)\n20. [NCT01060384](https://clinicaltrials.gov/ct2/show/NCT01060384)\n21. [NCT01919619](https://clinicaltrials.gov/ct2/show/NCT01919619)\n22. [NCT00864942](https://clinicaltrials.gov/ct2/show/NCT00864942)\n23. [NCT00413036](https://clinicaltrials.gov/ct2/show/NCT00413036)\n24. [NCT04578600](https://clinicaltrials.gov/ct2/show/NCT04578600)\n25. [NCT01476787](https://clinicaltrials.gov/ct2/show/NCT01476787)\n26. [NCT01076543](https://clinicaltrials.gov/ct2/show/NCT01076543)\n27. [NCT00294632](https://clinicaltrials.gov/ct2/show/NCT00294632)\n28. [NCT01254578](https://clinicaltrials.gov/ct2/show/NCT01254578)\n29. [NCT00765245](https://clinicaltrials.gov/ct2/show/NCT00765245)\n\nEach link will take you to the corresponding ClinicalTrials.gov page for more details about the study.",
  "20": "The unique PMID of the article titled “Complexity of neuro-oncological in-hospital consultations: a multicentre study” by first author Jauregui Larrañaga C, published in Neurologia in 2025, is 40306462.",
  "21": "Here are some of the completed interventional studies for Type 2 Diabetes Mellitus that started in August 2007 in the United States, based on ClinicalTrials.gov:\n\n1. [NCT02202876](https://clinicaltrials.gov/ct2/show/NCT02202876)\n2. [NCT01517373](https://clinicaltrials.gov/ct2/show/NCT01517373)\n3. [NCT00935220](https://clinicaltrials.gov/ct2/show/NCT00935220)\n4. [NCT01654120](https://clinicaltrials.gov/ct2/show/NCT01654120)\n5. [NCT01073020](https://clinicaltrials.gov/ct2/show/NCT01073020)\n6. [NCT02197520](https://clinicaltrials.gov/ct2/show/NCT02197520)\n7. [NCT01676220](https://clinicaltrials.gov/ct2/show/NCT01676220)\n8. [NCT03653091](https://clinicaltrials.gov/ct2/show/NCT03653091)\n9. [NCT04347291](https://clinicaltrials.gov/ct2/show/NCT04347291)\n10. [NCT02432391](https://clinicaltrials.gov/ct2/show/NCT02432391)\n\nThese are selected from a longer list, and each entry links to the full study details on ClinicalTrials.gov.",
  "22": "[ERROR] 'NoneType' object is not subscriptable",
  "23": "The target ADRB1 (Ensembl ID ENSG00000043591) is associated with the following diseases, with a minimum relevance score of 0.5 according to OpenTargets:\n\n1. **Hypertension** (Score: 0.738)\n2. **Cardiovascular disease** (Score: 0.723)\n3. **Myocardial infarction** (Score: 0.621)\n4. **Open-angle glaucoma** (Score: 0.605)\n5. **Glaucoma** (Score: 0.605)\n6. **Heart failure** (Score: 0.605)\n7. **Angina pectoris** (Score: 0.604)\n8. **Ocular hypertension** (Score: 0.602)\n9. **Migraine disorder** (Score: 0.602)\n10. **Congestive heart failure** (Score: 0.597)\n11. **Asthma** (Score: 0.596)\n12. **Sudden cardiac arrest** (Score: 0.590)\n13. **Ventricular arrhythmia** (Score: 0.583)\n14. **Sepsis** (Score: 0.582)\n15. **Pain** (Score: 0.581)\n16. **Sinusitis** (Score: 0.581)\n17. **Hypotension** (Score: 0.577)\n18. **Stroke** (Score: 0.576)\n19. **High density lipoprotein cholesterol measurement** (Score: 0.573)\n20. **Septic shock** (Score: 0.566)\n21. **Systolic blood pressure** (Score: 0.561)\n22. **Triglyceride measurement** (Score: 0.560)\n23. **Atrial fibrillation** (Score: 0.560)\n24. **Allergic disease** (Score: 0.559)\n25. **Diastolic blood pressure** (Score: 0.552)\n\nThese associations indicate a range of cardiovascular and ocular conditions, among others, linked to ADRB1.",
  "24": "The interventional studies for Type 2 Diabetes Mellitus involving exenatide or long-acting release exenatide that started in April 2006 in the United States are as follows:\n\n1. [NCT00803920](https://clinicaltrials.gov/ct2/show/NCT00803920)\n2. [NCT00637273](https://clinicaltrials.gov/ct2/show/NCT00637273)\n3. [NCT00806520](https://clinicaltrials.gov/ct2/show/NCT00806520)\n4. [NCT00308139](https://clinicaltrials.gov/ct2/show/NCT00308139)\n5. [NCT00641056](https://clinicaltrials.gov/ct2/show/NCT00641056)\n\nThese studies can be found on the ClinicalTrials.gov website for more detailed information.",
  "25": "The target ENSG00000015413, also known as DPEP1, is associated with the following diseases, each having a relevance score of at least 0.5 according to OpenTargets:\n\n1. **Infection** - Score: 0.579\n2. **Urinary Tract Infection** - Score: 0.572\n3. **Body Height** - Score: 0.569\n4. **Sepsis** - Score: 0.566\n5. **Pneumonia** - Score: 0.565\n6. **Diastolic Blood Pressure** - Score: 0.563\n7. **Endocarditis** - Score: 0.559\n8. **Cysteinylglycine Measurement** - Score: 0.557\n9. **Cys-gly, Oxidized Measurement** - Score: 0.553\n10. **Cysteinylglycine Disulfide Measurement** - Score: 0.545\n11. **Osteoarthritis** - Score: 0.522\n\nThese diseases have been associated with the DPEP1 target based on the specified minimum relevance score.",
  "26": "Here are some completed interventional studies for leukemia that started in July 2001 in the United States, based on the ClinicalTrials.gov database:\n\n1. [NCT00496873](https://clinicaltrials.gov/ct2/show/NCT00496873)\n2. [NCT01700673](https://clinicaltrials.gov/ct2/show/NCT01700673)\n3. [NCT01323920](https://clinicaltrials.gov/ct2/show/NCT01323920)\n4. [NCT01336920](https://clinicaltrials.gov/ct2/show/NCT01336920)\n5. [NCT02397720](https://clinicaltrials.gov/ct2/show/NCT02397720)\n6. [NCT03045120](https://clinicaltrials.gov/ct2/show/NCT03045120)\n7. [NCT00052520](https://clinicaltrials.gov/ct2/show/NCT00052520)\n8. [NCT00504920](https://clinicaltrials.gov/ct2/show/NCT00504920)\n9. [NCT00324220](https://clinicaltrials.gov/ct2/show/NCT00324220)\n10. [NCT01772420](https://clinicaltrials.gov/ct2/show/NCT01772420)\n\nThese links lead to the study details on ClinicalTrials.gov.",
  "27": "I couldn't find the PMID for the article titled “Hepatology in the Digital Era: A Review of Telehealth Care for Liver Disease” authored by Bloomberg L and published in Current Gastroenterology Reports in 2025. It's possible that the article is not available in the PubMed database yet, or there might be an error in the details provided. Please verify the information and try again later.",
  "28": "[ERROR] HTTPSConnectionPool(host='eutils.ncbi.nlm.nih.gov', port=443): Max retries exceeded with url: /entrez/eutils/esearch.fcgi?db=pubmed&term=Siegmund+B+Transition+in+gastroenterology+and+hepatology+Innere+Medizin+%28Heidelberg%2C+Germany%29+2025&retmode=json&sort=pub%2Bdate&retmax=10 (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x7f79be623850>: Failed to establish a new connection: [Errno 111] Connection refused'))",
  "29": "The diseases associated with the target MTOR (Ensembl ID ENSG00000198793) in OpenTargets, with a minimum relevance score of 0.5, are:\n\n1. **Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome**\n   - Relevance Score: 0.83\n\n2. **Isolated focal cortical dysplasia type II**\n   - Relevance Score: 0.82\n\n3. **Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes**\n   - Relevance Score: 0.65\n\n4. **Neurodegenerative disease**\n   - Relevance Score: 0.56\n\n5. **Clear cell renal carcinoma**\n   - Relevance Score: 0.54\n\n6. **CEBALID syndrome**\n   - Relevance Score: 0.52",
  "30": "Here are some completed interventional studies concerning Myelodysplastic Syndromes involving Azacitidine that started in November 2003 in the United States:\n\n1. [NCT01700673](https://clinicaltrials.gov/ct2/show/NCT01700673)\n2. [NCT02397720](https://clinicaltrials.gov/ct2/show/NCT02397720)\n3. [NCT00324220](https://clinicaltrials.gov/ct2/show/NCT00324220)\n4. [NCT02129101](https://clinicaltrials.gov/ct2/show/NCT02129101)\n5. [NCT00352001](https://clinicaltrials.gov/ct2/show/NCT00352001)\n\nThese are some examples, and more studies may be available. Let me know if you want further details about any of these studies!",
  "31": "The target IL13, with Ensembl ID ENSG00000169194, is associated with the following diseases in OpenTargets with a minimum relevance score of 0.5:\n\n1. **Atopic eczema** with a relevance score of 0.699.\n2. **Asthma** with a relevance score of 0.678.\n3. **Eczematoid dermatitis** with a relevance score of 0.615.\n4. **Allergic rhinitis** with a relevance score of 0.567.\n5. **Psoriasis** with a relevance score of 0.549.",
  "32": "The following are completed interventional studies that investigated Atorvastatin for Cardiovascular Disease, Cerebrovascular Accident, or Coronary Heart Disease in the United States and started in April 1998:\n\n1. [NCT00327691](https://clinicaltrials.gov/ct2/show/NCT00327691)\n2. [NCT00293748](https://clinicaltrials.gov/ct2/show/NCT00293748)",
  "33": "The diseases associated with the target ANGPT1 (Ensembl ID ENSG00000154188) in OpenTargets with a minimum relevance score of 0.5 are:\n\n1. **Open-Angle Glaucoma** (EFO_0004190) with a score of 0.5479\n2. **Intraocular Pressure Measurement** (EFO_0004695) with a score of 0.5126",
  "34": "The PMID for the article titled \"The challenges of indexing and impact factor in Latin American cardiology journals,\" authored by Piskorz DL and published in Archivos de cardiologia de Mexico, is 40445929.",
  "35": "Here are the completed interventional studies for Migraine Disorders that started in July 2008 in the United States:\n\n1. [NCT03700320](https://clinicaltrials.gov/show/NCT03700320)\n2. [NCT03337620](https://clinicaltrials.gov/show/NCT03337620)\n3. [NCT01516892](https://clinicaltrials.gov/show/NCT01516892)\n4. [NCT02933060](https://clinicaltrials.gov/show/NCT02933060)\n5. [NCT02847494](https://clinicaltrials.gov/show/NCT02847494)\n6. [NCT03706794](https://clinicaltrials.gov/show/NCT03706794)\n7. [NCT02021773](https://clinicaltrials.gov/show/NCT02021773)\n8. [NCT02287376](https://clinicaltrials.gov/show/NCT02287376)\n9. [NCT03901482](https://clinicaltrials.gov/show/NCT03901482)\n10. [NCT02905227](https://clinicaltrials.gov/show/NCT02905227)\n\nThese links direct you to the full details of each study on ClinicalTrials.gov.",
  "36": "Here are two interventional studies for Clostridium Infections or Diarrhea involving PAR-101/OPT-80 or Vancomycin that started in October 2006 in the United States:\n\n1. [NCT00468728](https://clinicaltrials.gov/ct2/show/NCT00468728)\n2. [NCT02692651](https://clinicaltrials.gov/ct2/show/NCT02692651)",
  "37": "The target GABRA2 (Ensembl ID ENSG00000151834) is associated with the following diseases with a minimum relevance score of 0.5 in OpenTargets:\n\n1. **Alcohol Dependence**: Score 0.68\n2. **Epilepsy**: Score 0.61\n3. **Major Depressive Disorder**: Score 0.61\n4. **Insomnia**: Score 0.61\n5. **Panic Disorder**: Score 0.60\n6. **Agitation**: Score 0.60\n7. **Anxiety Disorder**: Score 0.60\n8. **Anxiety**: Score 0.60\n9. **Migraine Disorder**: Score 0.60\n10. **Seizure**: Score 0.59\n11. **Pain**: Score 0.58\n12. **Depressive Disorder**: Score 0.57\n13. **Generalized Anxiety Disorder**: Score 0.56\n14. **Postpartum Depression**: Score 0.56\n15. **Lennox-Gastaut Syndrome**: Score 0.55\n16. **Status Epilepticus**: Score 0.55\n17. **Developmental and Epileptic Encephalopathy**: Score 0.54\n18. **Stiff-Person Syndrome**: Score 0.53\n\nThese diseases are identified as being relevant to GABRA2 according to the data from OpenTargets.",
  "38": "The unique PMID for the article titled “[Comments of the German Society for Orthopaedic Rheumatology on the article \"Rheumatological care in Germany\" : Memorandum of the German Society for Rheumatology and Clinical Immunology 2024],” authored by Carl HD and published in Zeitschrift fur Rheumatologie in 2025 is 40167622.",
  "39": "The following interventional studies for Relapsing-Remitting Multiple Sclerosis with BG00012 as a main intervention started in January 2007 in the United States:\n\n1. [NCT02159573](https://clinicaltrials.gov/ct2/show/NCT02159573)\n2. [NCT02525874](https://clinicaltrials.gov/ct2/show/NCT02525874)\n3. [NCT02776072](https://clinicaltrials.gov/ct2/show/NCT02776072)\n4. [NCT00420212](https://clinicaltrials.gov/ct2/show/NCT00420212)\n5. [NCT03870763](https://clinicaltrials.gov/ct2/show/NCT03870763)\n6. [NCT02217982](https://clinicaltrials.gov/ct2/show/NCT02217982)\n7. [NCT03093324](https://clinicaltrials.gov/ct2/show/NCT03093324)\n8. [NCT02419638](https://clinicaltrials.gov/ct2/show/NCT02419638)\n9. [NCT02675413](https://clinicaltrials.gov/ct2/show/NCT02675413)\n10. [NCT02218879](https://clinicaltrials.gov/ct2/show/NCT02218879)\n11. [NCT03284970](https://clinicaltrials.gov/ct2/show/NCT03284970)\n12. [NCT00835770](https://clinicaltrials.gov/ct2/show/NCT00835770)\n13. [NCT01945359](https://clinicaltrials.gov/ct2/show/NCT01945359)\n14. [NCT02410200](https://clinicaltrials.gov/ct2/show/NCT02410200)\n15. [NCT02555215](https://clinicaltrials.gov/ct2/show/NCT02555215)\n16. [NCT02634307](https://clinicaltrials.gov/ct2/show/NCT02634307)\n17. [NCT01156311](https://clinicaltrials.gov/ct2/show/NCT01156311)\n18. [NCT03535298](https://clinicaltrials.gov/ct2/show/NCT03535298)\n19. [NCT03500328](https://clinicaltrials.gov/ct2/show/NCT03500328)\n20. [NCT02283853](https://clinicaltrials.gov/ct2/show/NCT02283853)\n21. [NCT00451451](https://clinicaltrials.gov/ct2/show/NCT00451451)\n22. [NCT02823951](https://clinicaltrials.gov/ct2/show/NCT02823951)\n\nThese trials are registered on ClinicalTrials.gov, and you can click on each NCT ID to view more details about the respective study.",
  "40": "For the target with Ensembl ID ENSG00000196230 and approved symbol TUBB, the following tractability information is available where the value is true:\n\n### Small Molecule (SM)\n- **Approved Drug**: There is an approved drug available.\n- **Structure with Ligand**: Structural information with a ligand is available.\n- **High-Quality Ligand**: High-quality ligand information is available.\n- **Druggable Family**: It belongs to a druggable family.\n\n### Antibody (AB)\n- **GO CC high conf**: High confidence cellular component according to Gene Ontology.\n\n### Proteolysis-targeting molecule (PR)\n- **UniProt Ubiquitination**: Ubiquitination data available from UniProt.\n- **Database Ubiquitination**: Ubiquitination data available in various databases.\n- **Half-life Data**: There is data available on the half-life.\n- **Small Molecule Binder**: It binds to a small molecule.\n\n### Oligonucleotide (OC)\n- **Approved Drug**: There is an approved oligonucleotide drug available.",
  "41": "Here are the completed interventional studies conducted in the United States for Type 2 Diabetes Mellitus involving Exenatide Once Weekly:\n\n1. [NCT00803920](https://clinicaltrials.gov/ct2/show/NCT00803920)\n2. [NCT01652729](https://clinicaltrials.gov/ct2/show/NCT01652729)\n3. [NCT01104701](https://clinicaltrials.gov/ct2/show/NCT01104701)\n4. [NCT00637273](https://clinicaltrials.gov/ct2/show/NCT00637273)\n5. [NCT00806520](https://clinicaltrials.gov/ct2/show/NCT00806520)\n6. [NCT02288273](https://clinicaltrials.gov/ct2/show/NCT02288273)\n7. [NCT02917057](https://clinicaltrials.gov/ct2/show/NCT02917057)\n8. [NCT00717457](https://clinicaltrials.gov/ct2/show/NCT00717457)\n9. [NCT03970044](https://clinicaltrials.gov/ct2/show/NCT03970044)\n10. [NCT02974244](https://clinicaltrials.gov/ct2/show/NCT02974244)\n11. [NCT02981069](https://clinicaltrials.gov/ct2/show/NCT02981069)\n12. [NCT00103935](https://clinicaltrials.gov/ct2/show/NCT00103935)\n13. [NCT00308139](https://clinicaltrials.gov/ct2/show/NCT00308139)\n14. [NCT00894322](https://clinicaltrials.gov/ct2/show/NCT00894322)\n15. [NCT00753896](https://clinicaltrials.gov/ct2/show/NCT00753896)\n16. [NCT02229396](https://clinicaltrials.gov/ct2/show/NCT02229396)\n17. [NCT02251431](https://clinicaltrials.gov/ct2/show/NCT02251431)\n18. [NCT01652716](https://clinicaltrials.gov/ct2/show/NCT01652716)\n19. [NCT01885208](https://clinicaltrials.gov/ct2/show/NCT01885208)\n20. [NCT02119819](https://clinicaltrials.gov/ct2/show/NCT02119819)\n21. [NCT01554618](https://clinicaltrials.gov/ct2/show/NCT01554618)\n22. [NCT02843399](https://clinicaltrials.gov/ct2/show/NCT02843399)\n23. [NCT01144338](https://clinicaltrials.gov/ct2/show/NCT01144338)\n24. [NCT01064687](https://clinicaltrials.gov/ct2/show/NCT01064687)\n25. [NCT00641056](https://clinicaltrials.gov/ct2/show/NCT00641056)\n26. [NCT00676338](https://clinicaltrials.gov/ct2/show/NCT00676338)\n27. [NCT00877890](https://clinicaltrials.gov/ct2/show/NCT00877890)\n28. [NCT02229383](https://clinicaltrials.gov/ct2/show/NCT02229383)\n\nYou can click on the links to view more details about each study.",
  "42": "The PMID of the article titled \"[Practical guideline for short bowel syndrome]\" by first author Dabsch S, published in Zeitschrift fur Gastroenterologie in 2025, is 40360142.",
  "43": "Here are the completed interventional studies for multiple myeloma involving carfilzomib, started in August 2007 or later in the United States, as listed on ClinicalTrials.gov:\n\n1. [NCT00963820](https://clinicaltrials.gov/ct2/show/NCT00963820)\n2. [NCT03859427](https://clinicaltrials.gov/ct2/show/NCT03859427)\n3. [NCT01549431](https://clinicaltrials.gov/ct2/show/NCT01549431)\n4. [NCT01080391](https://clinicaltrials.gov/ct2/show/NCT01080391)\n5. [NCT03412565](https://clinicaltrials.gov/ct2/show/NCT03412565)\n6. [NCT01962792](https://clinicaltrials.gov/ct2/show/NCT01962792)\n7. [NCT01980589](https://clinicaltrials.gov/ct2/show/NCT01980589)\n8. [NCT01572480](https://clinicaltrials.gov/ct2/show/NCT01572480)\n9. [NCT03375567](https://clinicaltrials.gov/ct2/show/NCT03375567)\n10. [NCT01568866](https://clinicaltrials.gov/ct2/show/NCT01568866)\n11. [NCT01989325](https://clinicaltrials.gov/ct2/show/NCT01989325)\n12. [NCT01372540](https://clinicaltrials.gov/ct2/show/NCT01372540)\n13. [NCT02101944](https://clinicaltrials.gov/ct2/show/NCT02101944)\n14. [NCT00884312](https://clinicaltrials.gov/ct2/show/NCT00884312)\n15. [NCT01246063](https://clinicaltrials.gov/ct2/show/NCT01246063)\n16. [NCT01057225](https://clinicaltrials.gov/ct2/show/NCT01057225)\n17. [NCT01677858](https://clinicaltrials.gov/ct2/show/NCT01677858)\n18. [NCT04191616](https://clinicaltrials.gov/ct2/show/NCT04191616)\n19. [NCT02206425](https://clinicaltrials.gov/ct2/show/NCT02206425)\n20. [NCT02095834](https://clinicaltrials.gov/ct2/show/NCT02095834)\n21. [NCT00530816](https://clinicaltrials.gov/ct2/show/NCT00530816)\n22. [NCT00721734](https://clinicaltrials.gov/ct2/show/NCT00721734)\n23. [NCT05556616](https://clinicaltrials.gov/ct2/show/NCT05556616)\n24. [NCT01660750](https://clinicaltrials.gov/ct2/show/NCT01660750)\n25. [NCT01842308](https://clinicaltrials.gov/ct2/show/NCT01842308)\n26. [NCT00511238](https://clinicaltrials.gov/ct2/show/NCT00511238)\n27. [NCT01351623](https://clinicaltrials.gov/ct2/show/NCT01351623)\n28. [NCT02148913](https://clinicaltrials.gov/ct2/show/NCT02148913)\n29. [NCT01496118](https://clinicaltrials.gov/ct2/show/NCT01496118)\n30. [NCT03605719](https://clinicaltrials.gov/ct2/show/NCT03605719)\n31. [NCT00531284](https://clinicaltrials.gov/ct2/show/NCT00531284)\n32. [NCT02178579](https://clinicaltrials.gov/ct2/show/NCT02178579)\n33. [NCT02145403](https://clinicaltrials.gov/ct2/show/NCT02145403)\n34. [NCT01204164](https://clinicaltrials.gov/ct2/show/NCT01204164)\n35. [NCT01402284](https://clinicaltrials.gov/ct2/show/NCT01402284)\n36. [NCT03361306](https://clinicaltrials.gov/ct2/show/NCT03361306)\n37. [NCT01818752](https://clinicaltrials.gov/ct2/show/NCT01818752)\n38. [NCT03275285](https://clinicaltrials.gov/ct2/show/NCT03275285)\n39. [NCT01365559](https://clinicaltrials.gov/ct2/show/NCT01365559)\n40. [NCT03773107](https://clinicaltrials.gov/ct2/show/NCT03773107)\n41. [NCT01301807](https://clinicaltrials.gov/ct2/show/NCT01301807)\n42. [NCT02336815](https://clinicaltrials.gov/ct2/show/NCT02336815)\n43. [NCT01690143](https://clinicaltrials.gov/ct2/show/NCT01690143)\n44. [NCT03224507](https://clinicaltrials.gov/ct2/show/NCT03224507)\n45. [NCT01949532](https://clinicaltrials.gov/ct2/show/NCT01949532)\n46. [NCT03158688](https://clinicaltrials.gov/ct2/show/NCT03158688)\n47. [NCT02412878](https://clinicaltrials.gov/ct2/show/NCT02412878)\n48. [NCT01998971](https://clinicaltrials.gov/ct2/show/NCT01998971)\n49. [NCT02937571](https://clinicaltrials.gov/ct2/show/NCT02937571)\n50. [NCT01903811](https://clinicaltrials.gov/ct2/show/NCT01903811)\n51. [NCT02335983](https://clinicaltrials.gov/ct2/show/NCT02335983)\n52. [NCT00932698](https://clinicaltrials.gov/ct2/show/NCT00932698)\n53. [NCT00603447](https://clinicaltrials.gov/ct2/show/NCT00603447)\n54. [NCT01775553](https://clinicaltrials.gov/ct2/show/NCT01775553)\n55. [NCT01029054](https://clinicaltrials.gov/ct2/show/NCT01029054)\n\nYou can click on each NCT identifier to get more details about the individual trials.",
  "44": "The target TYMS (Ensembl ID ENSG00000176890) is associated with several diseases in OpenTargets with a minimum relevance score of 0.5. Here are the diseases and their scores:\n\n1. Dyskeratosis congenita, digenic - Score: 0.662\n2. Breast cancer - Score: 0.616\n3. Neoplasm - Score: 0.613\n4. Dyskeratosis congenita - Score: 0.598\n5. Non-small cell lung carcinoma - Score: 0.594\n6. Breast carcinoma - Score: 0.580\n7. Colonic neoplasm - Score: 0.576\n8. Actinic keratosis - Score: 0.571\n9. Colorectal neoplasm - Score: 0.554\n10. Breast neoplasm - Score: 0.553\n11. Mesothelioma - Score: 0.547\n12. Stomach neoplasm - Score: 0.528\n13. Gastric adenocarcinoma - Score: 0.524\n14. Adenocarcinoma - Score: 0.509\n15. Arabonate measurement - Score: 0.501\n\nThese associations indicate potential links between the TYMS gene and these diseases, based on available data in OpenTargets.",
  "45": "For the target with Ensembl ID ENSG00000163599 and symbol CTLA4, the tractability information where the value is True includes the following modalities:\n\n1. **SM (Small Molecule)**\n   - Structure with Ligand\n\n2. **AB (Antibody)**\n   - Approved Drug\n   - UniProt loc high confidence\n   - GO CC high confidence\n   - UniProt SigP or TMHMM\n\nThese modalities indicate the potential approaches for developing therapeutics targeting CTLA4.",
  "46": "Here are some of the completed interventional studies for chronic myelogenous leukemia that started in July 2007 in the United States:\n\n1. [NCT02397720](https://clinicaltrials.gov/ct2/show/NCT02397720)\n2. [NCT03045120](https://clinicaltrials.gov/ct2/show/NCT03045120)\n3. [NCT01772420](https://clinicaltrials.gov/ct2/show/NCT01772420)\n4. [NCT00469729](https://clinicaltrials.gov/ct2/show/NCT00469729)\n5. [NCT03578367](https://clinicaltrials.gov/ct2/show/NCT03578367)\n6. [NCT02129101](https://clinicaltrials.gov/ct2/show/NCT02129101)\n7. [NCT01607892](https://clinicaltrials.gov/ct2/show/NCT01607892)\n8. [NCT01053494](https://clinicaltrials.gov/ct2/show/NCT01053494)\n9. [NCT00660920](https://clinicaltrials.gov/ct2/show/NCT00660920)\n10. [NCT01629082](https://clinicaltrials.gov/ct2/show/NCT01629082)\n\nPlease check the ClinicalTrials.gov website for detailed information about each of these studies.",
  "47": "Here is the tractability information for the target with Ensembl ID ENSG00000117601 and approved symbol SERPINC1, where the value is True:\n\n1. **Small Molecule (SM)**:\n   - Structure with Ligand\n   - High-Quality Pocket\n   - Druggable Family\n\n2. **Antibody (AB)**:\n   - GO CC high confidence\n   - UniProt location medium confidence\n   - UniProt Signal Peptide or TMHMM\n\n3. **Protein Replacement (PR)**:\n   - Small Molecule Binder\n\n4. **Other Therapeutic Class (OC)**:\n   - Approved Drug",
  "48": "The tractability information for the target with Ensembl ID ENSG00000091879 (approved symbol ANGPT2) in the OpenTargets platform, where the value is True, includes the following modalities:\n\n1. **Approved Drug**: The target is associated with an approved drug.\n2. **UniProt loc high conf**: High confidence localization according to UniProt.\n3. **GO CC high conf**: High confidence based on Gene Ontology Cellular Component annotations.\n4. **UniProt SigP or TMHMM**: Signal peptide or transmembrane domain predictions according to UniProt.\n5. **Advanced Clinical**: The target is involved in advanced clinical stages.",
  "49": "There are no interventional studies for Heart Failure, Congestive or Dilated Cardiomyopathy that started in March 2007 in the United States and are currently recruiting according to the available records on ClinicalTrials.gov.",
  "50": "I couldn't find a PubMed ID for the article titled “Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study” authored by Salmanizadeh F in the 2025 BMC Gastroenterology journal. It's possible that the article is not indexed in PubMed yet, or there may be an error in the details provided.",
  "51": "The completed interventional studies for Multiple Sclerosis involving Fingolimod 1.25 mg as an intervention, which started in May 2006 in the United States, are:\n\n1. [NCT00355134](https://clinicaltrials.gov/ct2/show/NCT00355134)\n2. [NCT00340834](https://clinicaltrials.gov/ct2/show/NCT00340834)\n3. [NCT03623243](https://clinicaltrials.gov/ct2/show/NCT03623243)",
  "52": "The PMID of the article titled \"[Evidence-based guidelines in gastroenterological medical care: a survey among members of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) on acceptance, application and optimization]\" authored by Bachmann J and published in Zeitschrift fur Gastroenterologie in 2025 is 40306647.",
  "53": "The target DRD2 (Ensembl ID ENSG00000149295) is associated with the following diseases, each having a minimum relevance score of 0.5 in OpenTargets:\n\n1. Major depressive disorder - Score: 0.731\n2. Schizophrenia - Score: 0.705\n3. Bipolar disorder - Score: 0.685\n4. Mental or behavioural disorder - Score: 0.641\n5. Parkinson disease - Score: 0.637\n6. Tourette syndrome - Score: 0.629\n7. Autism - Score: 0.616\n8. Psychosis - Score: 0.615\n9. Schizoaffective disorder - Score: 0.606\n10. Bipolar I disorder - Score: 0.603\n11. Agitation - Score: 0.600\n12. Aggressive behavior - Score: 0.599\n13. Restless legs syndrome - Score: 0.593\n14. Depressive disorder - Score: 0.590\n15. Nausea and vomiting - Score: 0.575\n16. Post-operative nausea and vomiting - Score: 0.569\n17. Type 2 diabetes mellitus - Score: 0.547\n18. Gastrointestinal disease - Score: 0.538\n19. Hypogonadism - Score: 0.526\n20. Conduct disorder - Score: 0.520\n21. Hyperprolactinemia - Score: 0.516\n22. Infertility - Score: 0.513\n23. Acromegaly - Score: 0.504",
  "54": "Yes, the tractability information for the target with Ensembl ID ENSG00000185499 and approved symbol MUC1 indicates that multiple modalities have the value set to True. These modalities include:\n\n- SM (Small Molecule):\n  - Structure with Ligand\n  - Med-Quality Pocket\n\n- AB (Antibody):\n  - Advanced Clinical\n  - UniProt loc high conf\n  - GO CC high conf\n  - UniProt loc med conf\n  - UniProt SigP or TMHMM\n  - Human Protein Atlas loc\n\n- OC (Overall Clinical):\n  - Advanced Clinical\n\nThis confirms that MUC1 is considered tractable in several modalities according to OpenTargets.",
  "55": "Here are some completed interventional studies for Multiple Sclerosis involving Fingolimod that started in June 2006 in the United States:\n\n1. [NCT01442194](https://clinicaltrials.gov/ct2/show/NCT01442194)\n2. [NCT00355134](https://clinicaltrials.gov/ct2/show/NCT00355134)\n\nFor more detailed information, you can view the specific trials using their respective NCT IDs on ClinicalTrials.gov.",
  "56": "Here are the interventional studies for Hepatitis C involving Pegylated Interferon Alfa 2a that were started in March 2008 in the United States:\n\n1. [NCT01405027](https://clinicaltrials.gov/ct2/show/NCT01405027)\n2. [NCT01439373](https://clinicaltrials.gov/ct2/show/NCT01439373)\n3. [NCT00984620](https://clinicaltrials.gov/ct2/show/NCT00984620)\n4. [NCT01485991](https://clinicaltrials.gov/ct2/show/NCT01485991)\n5. [NCT01323244](https://clinicaltrials.gov/ct2/show/NCT01323244)\n6. [NCT01447394](https://clinicaltrials.gov/ct2/show/NCT01447394)\n7. [NCT01471574](https://clinicaltrials.gov/ct2/show/NCT01471574)\n8. [NCT01054573](https://clinicaltrials.gov/ct2/show/NCT01054573)\n9. [NCT00845676](https://clinicaltrials.gov/ct2/show/NCT00845676)\n10. [NCT01241760](https://clinicaltrials.gov/ct2/show/NCT01241760)\n\nThese studies are accessible via the provided links for more detailed information.",
  "57": "The unique PubMed ID (PMID) for the article titled \"Evolution of enterology as a science\" by Sabelnikova EA, published in Terapevticheskii arkhiv in 2025, is 40237759.",
  "58": "The tractability information available for the target with Ensembl ID ENSG00000142208 (AKT1), where the value is True, includes the following modalities:\n\n- **SM (Small Molecule)**\n  - Advanced Clinical\n  - Structure with Ligand\n  - High-Quality Ligand\n  - High-Quality Pocket\n  - Druggable Family\n\n- **AB (Antibody)**\n  - UniProt loc high conf\n  - GO CC high conf\n\n- **PR (Proteolysis Targeting)**\n  - Literature\n  - UniProt Ubiquitination\n  - Database Ubiquitination\n  - Half-life Data\n  - Small Molecule Binder\n\nThese indicators reflect various aspects of the tractability of AKT1 as a drug target.",
  "59": "Here are some interventional studies for Melanoma that involve ipilimumab as the main intervention and started in April 2006 in the United States:\n\n1. [NCT03033576](https://clinicaltrials.gov/ct2/show/NCT03033576)\n2. [NCT02158520](https://clinicaltrials.gov/ct2/show/NCT02158520)\n3. [NCT01608594](https://clinicaltrials.gov/ct2/show/NCT01608594)\n4. [NCT03732560](https://clinicaltrials.gov/ct2/show/NCT03732560)\n5. [NCT04697576](https://clinicaltrials.gov/ct2/show/NCT04697576)\n\nIf you need more information on any specific study, please let me know!",
  "60": "For the target with Ensembl ID ENSG00000151834 and approved symbol GABRA2, the OpenTargets platform provides the following tractability information where the value is true:\n\n### Small Molecule (SM)\n- **Approved Drug**: The target is associated with approved drugs.\n- **High-Quality Ligand**: The target has high-quality ligands.\n- **Druggable Family**: The target belongs to a druggable family.\n\n### Antibody (AB)\n- **GO CC High Confidence**: High confidence Gene Ontology cellular component annotations.\n- **UniProt Localization Medium Confidence**: Medium confidence annotations for localization according to UniProt.\n- **UniProt Signal Peptides or TMHMM Predictions**: The target is associated with signal peptides or transmembrane helix predictions.\n- **Human Protein Atlas Localization**: Localization data from the Human Protein Atlas.\n\n### PROTAC (PR)\n- **Half-life Data**: There is data available on the protein's half-life.\n- **Small Molecule Binder**: The target binds small molecules efficiently.\n\nThese modalities indicate potential avenues for drug development and research targeting GABRA2.",
  "61": "The completed interventional studies for Multiple Sclerosis involving Laquinimod that started in November 2007 in the United States are:\n\n1. [NCT01707992](https://clinicaltrials.gov/ct2/show/NCT01707992)\n2. [NCT02284568](https://clinicaltrials.gov/ct2/show/NCT02284568)\n3. [NCT00605215](https://clinicaltrials.gov/ct2/show/NCT00605215)\n4. [NCT00509145](https://clinicaltrials.gov/ct2/show/NCT00509145)",
  "62": "The tractability information available for the target with Ensembl ID ENSG00000176890 and approved symbol TYMS, where the value is True, includes the following modalities:\n\n### Small Molecules (SM)\n- **Approved Drug**\n- **Structure with Ligand**\n- **High-Quality Ligand**\n- **High-Quality Pocket**\n- **Druggable Family**\n\n### Protein Reagents (PR)\n- **UniProt Ubiquitination**\n- **Database Ubiquitination**\n- **Small Molecule Binder**",
  "63": "The PMID for the article titled \"[Allergology: what's new in 2024],\" authored by Pérez-Codesido S and published in Revue medicale suisse in 2025, is 39812277.",
  "64": "The unique PMID for the article titled \"The State of Immunology in Allergy and Immunology Fellowship,\" authored by Tran HN and published in Immunology and Allergy Clinics of North America in 2025, is 40287165.",
  "65": "It seems I couldn't find the article titled \"Causal association between gut microbiota and endometrial cancer in European and East Asian populations: a two-sample Mendelian randomization study\" authored by Chen J and published in BMC Women's Health in 2025. It's possible that the article has not been indexed in PubMed yet or there might be an error in the details provided. Please double-check the information and try again later.",
  "66": "I couldn't find the PMID for the article titled “Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics,” authored by Rosenbloom M and published in the Journal of Neurology in 2025. It's possible that the article isn't indexed in PubMed yet, or there might be an error in the details provided. If you have any more details or corrections, please let me know!",
  "67": "The PMID of the article titled “Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing,” authored by Behel V and published in NPJ Systems Biology and Applications in 2025, is 40483308.",
  "68": "For the target with Ensembl ID ENSG00000188389 and approved symbol PDCD1, the following tractability information is available with a value of True:\n\n1. **Small Molecule (SM) Modality:**\n   - Structure with Ligand\n   - High-Quality Ligand\n\n2. **Antibody (AB) Modality:**\n   - Approved Drug\n   - UniProt loc high conf\n   - GO CC high conf\n   - UniProt SigP or TMHMM\n\n3. **Protein (PR) Modality:**\n   - Literature\n   - UniProt Ubiquitination\n   - Small Molecule Binder\n\n4. **Other Criteria (OC) Modality:**\n   - Advanced Clinical\n\nThese items indicate various tractability aspects of the target PDCD1, reflecting its potential as a druggable target in different contexts and phases of drug development.",
  "69": "The interventional study for Obesity or Type 2 Diabetes involving VI-0521 that started in November 2007 in the United States is registered with the identifier [NCT00553787](https://clinicaltrials.gov/ct2/show/NCT00553787).",
  "70": "[ERROR] (2006, \"MySQL server has gone away (TimeoutError(110, 'Connection timed out'))\")",
  "71": "The unique PubMed ID (PMID) for the article titled \"Assessing the prevalence, quality and compliance of data-sharing statements in gastroenterology publications: a cross-sectional analysis,\" authored by Moore J and published in BMJ Open in 2025, is 40132820.",
  "72": "Here are some interventional studies related to bone metastases that started in April 2006, using Denosumab or Zoledronic Acid as interventions:\n\n1. [NCT00321620](https://clinicaltrials.gov/ct2/show/NCT00321620)\n2. [NCT03958565](https://clinicaltrials.gov/ct2/show/NCT03958565)\n3. [NCT01920568](https://clinicaltrials.gov/ct2/show/NCT01920568)\n4. [NCT01345019](https://clinicaltrials.gov/ct2/show/NCT01345019)\n5. [NCT02274623](https://clinicaltrials.gov/ct2/show/NCT02274623)\n6. [NCT00321464](https://clinicaltrials.gov/ct2/show/NCT00321464)\n7. [NCT00330759](https://clinicaltrials.gov/ct2/show/NCT00330759)\n8. [NCT06374459](https://clinicaltrials.gov/ct2/show/NCT06374459)\n9. [NCT04549207](https://clinicaltrials.gov/ct2/show/NCT04549207)\n10. [NCT03408652](https://clinicaltrials.gov/ct2/show/NCT03408652)\n\nYou can click on the links for more details about each study.",
  "73": "For the target with Ensembl ID ENSG00000171105 and approved symbol INSR, the tractability information where the value is True is as follows:\n\n1. **Small Molecule (SM)**\n   - Advanced Clinical\n   - Structure with Ligand\n   - High-Quality Ligand\n   - High-Quality Pocket\n   - Druggable Family\n\n2. **Antibody (AB)**\n   - GO CC high conf\n   - UniProt loc med conf\n   - UniProt SigP or TMHMM\n   - Human Protein Atlas loc\n\n3. **PROTAC (PR)**\n   - Database Ubiquitination\n   - Half-life Data\n   - Small Molecule Binder\n\n4. **Other modalities (OC)**\n   - Approved Drug\n\nThese modalities suggest tractability in various aspects such as small molecule binding, antibody-based interactions, PROTAC-related potential, and existing drug approvals.",
  "74": "The target HMGCR (Ensembl ID ENSG00000113161) is associated with several diseases in OpenTargets, with a minimum relevance score of 0.5:\n\n1. **Coronary artery disease** - Score: 0.735\n2. **Hypercholesterolemia** - Score: 0.713\n3. **Familial hypercholesterolemia** - Score: 0.706\n4. **Stroke** - Score: 0.689\n5. **Cardiovascular disease** - Score: 0.668\n6. **Type 2 diabetes mellitus** - Score: 0.662\n7. **Hyperlipidemia** - Score: 0.635\n8. **Low density lipoprotein cholesterol measurement** - Score: 0.618\n9. **Myocardial infarction** - Score: 0.613\n10. **Angina pectoris** - Score: 0.606\n11. **Congestive heart failure** - Score: 0.602\n12. **Abnormal circulating lipid concentration** - Score: 0.601\n13. **Alzheimer disease** - Score: 0.587\n14. **Atherosclerosis** - Score: 0.586\n15. **Diabetes mellitus** - Score: 0.586\n16. **Apolipoprotein B measurement** - Score: 0.584\n17. **Total cholesterol measurement** - Score: 0.580\n18. **Hypertension** - Score: 0.579\n19. **Very low density lipoprotein cholesterol measurement** - Score: 0.577\n20. **Neurodegenerative disease** - Score: 0.570\n21. **Cholesteryl ester measurement** - Score: 0.568\n22. **Lipid measurement** - Score: 0.566\n23. **Phospholipids:total lipids ratio** - Score: 0.564\n24. **Cholesterol:total lipids ratio** - Score: 0.564\n25. **Multiple sclerosis** - Score: 0.563\n\nThese associations show various cardiovascular, metabolic, and neurodegenerative conditions linked to HMGCR.",
  "75": "I found several interventional studies for malignant melanoma that started recruiting in the United States in December 2005. Here are some of the NCT IDs for these studies:\n\n- [NCT06660420](https://www.clinicaltrials.gov/ct2/show/NCT06660420)\n- [NCT05039801](https://www.clinicaltrials.gov/ct2/show/NCT05039801)\n- [NCT01638676](https://www.clinicaltrials.gov/ct2/show/NCT01638676)\n- [NCT06432660](https://www.clinicaltrials.gov/ct2/show/NCT06432660)\n- [NCT05076760](https://www.clinicaltrials.gov/ct2/show/NCT05076760)\n\nThese are just a few of the studies. If you need more details, feel free to ask!",
  "76": "The target ENSG00000082175 (PGR) is associated with the following diseases in OpenTargets with a minimum relevance score of 0.5:\n\n1. Endometriosis (score: 0.657)\n2. Uterine fibroid (score: 0.651)\n3. Acne (score: 0.598)\n4. Hemorrhage (score: 0.576)\n5. Menorrhagia (score: 0.560)\n6. Premature birth (score: 0.552)\n7. Anorexia (score: 0.545)\n8. Amenorrhea (score: 0.538)\n9. Leiomyoma (score: 0.530)\n10. Cachexia (score: 0.526)\n11. Neoplasm (score: 0.525)\n12. Cushing syndrome (score: 0.511)\n13. Inborn error of immunity (score: 0.504)",
  "77": "The tractability information for the target PDGFRA (Ensembl ID: ENSG00000134853) with the value set to True is as follows:\n\n1. **Small Molecule (SM) Modality:**\n   - Approved Drug\n   - Structure with Ligand\n   - High-Quality Ligand\n   - Druggable Family\n\n2. **Antibody (AB) Modality:**\n   - Approved Drug\n   - UniProt loc high conf\n   - GO CC high conf\n   - UniProt SigP or TMHMM\n\n3. **Protein (PR) Modality:**\n   - UniProt Ubiquitination\n   - Database Ubiquitination\n   - Half-life Data\n   - Small Molecule Binder\n\n4. **Oligonucleotide (OC) Modality:**\n   - Approved Drug\n\nThese modalities and labels indicate various aspects under which PDGFRA is considered tractable for drug development.",
  "78": "The diseases associated with the target NR3C1 (Ensembl ID ENSG00000113580) with a minimum relevance score of 0.5 in OpenTargets are as follows:\n\n1. **Glucocorticoid Resistance** - Score: 0.7915\n2. **Chronic Obstructive Pulmonary Disease** - Score: 0.7046\n3. **Multiple Sclerosis** - Score: 0.6841\n4. **Frozen Shoulder** - Score: 0.6436\n5. **Rheumatoid Arthritis** - Score: 0.6318\n6. **Ulcerative Colitis** - Score: 0.6183\n7. **Autoimmune Thrombocytopenic Purpura** - Score: 0.6175\n8. **Infection** - Score: 0.6143\n9. **Sarcoidosis** - Score: 0.6122\n10. **Nephrotic Syndrome** - Score: 0.6104\n11. **Crohn's Disease** - Score: 0.6096\n12. **Asthma** - Score: 0.6093\n13. **Cancer** - Score: 0.6087\n14. **Lymphoma** - Score: 0.6085\n15. **Osteoarthritis** - Score: 0.6083\n16. **Atopic Eczema** - Score: 0.6075\n17. **Leukemia** - Score: 0.6072\n18. **Inflammation** - Score: 0.6070\n19. **Allergic Rhinitis** - Score: 0.6070\n20. **Psoriasis** - Score: 0.6061\n21. **Pneumonia** - Score: 0.6049\n22. **Skin Disease** - Score: 0.6042\n23. **Juvenile Idiopathic Arthritis** - Score: 0.6037\n24. **Seasonal Allergic Rhinitis** - Score: 0.6012\n25. **Psoriasis Vulgaris** - Score: 0.6004\n\nThese scores represent the relevance of the association between the target and the diseases.",
  "79": "The diseases associated with the target RAF1 (Ensembl ID ENSG00000132155) with a minimum relevance score of 0.5 in OpenTargets are:\n\n1. **Noonan syndrome** - Score: 0.87\n2. **Noonan syndrome with multiple lentigines** - Score: 0.81\n3. **Dilated cardiomyopathy** - Score: 0.75\n4. **Rasopathy** - Score: 0.68\n5. **Cancer** - Score: 0.63\n6. **Hypertrophic cardiomyopathy** - Score: 0.57\n7. **Costello syndrome** - Score: 0.56\n8. **Renal cell carcinoma** - Score: 0.53\n9. **Abnormality of the cardiovascular system** - Score: 0.53\n10. **Neoplasm** - Score: 0.52\n11. **Noonan syndrome and Noonan-related syndrome** - Score: 0.51\n12. **Hepatocellular carcinoma** - Score: 0.51",
  "80": "I couldn't find any articles with the title “Mapping training programs for endoscopy nurses in gastroenterology: a scoping review” by Parrella A, published in the European Journal of Gastroenterology & Hepatology in 2025. It's possible that the article hasn't been indexed in PubMed yet or the details provided may need verification.",
  "81": "I couldn't find a PubMed ID (PMID) for the 2025 article titled \"A decade of whole-exome sequencing in Brazilian Neurology: from past insights to future perspectives\" by Quaio CRDC in the journal \"Arquivos de Neuro-Psiquiatria.\" It is possible that the article is not yet indexed in PubMed or the details provided are incorrect. Please verify the information or check back later.",
  "82": "I found several clinical trials for Multiple Myeloma with the use of bortezomib that started in December 2004 in the United States. Here are the NCT IDs:\n\n1. [NCT01548573](https://clinicaltrials.gov/ct2/show/NCT01548573)\n2. [NCT02322320](https://clinicaltrials.gov/ct2/show/NCT02322320)\n3. [NCT00963820](https://clinicaltrials.gov/ct2/show/NCT00963820)\n4. [NCT02514382](https://clinicaltrials.gov/ct2/show/NCT02514382)\n5. [NCT04181827](https://clinicaltrials.gov/ct2/show/NCT04181827)\n6. [NCT04912427](https://clinicaltrials.gov/ct2/show/NCT04912427)\n7. [NCT03829020](https://clinicaltrials.gov/ct2/show/NCT03829020)\n8. [NCT01472627](https://clinicaltrials.gov/ct2/show/NCT01472627)\n9. [NCT01315873](https://clinicaltrials.gov/ct2/show/NCT01315873)\n10. [NCT01056276](https://clinicaltrials.gov/ct2/show/NCT01056276)\n\nFor more detailed information regarding each study, you can follow the respective links to their ClinicalTrials.gov pages.",
  "83": "It seems I couldn't find any article in the PubMed database matching the criteria you specified. The article \"How great was the influence of his origins and descendants on Charcot's behaviors?\" by Teive HAG in the 2025 Arquivos de Neuro-Psiquiatria might not yet be indexed in PubMed or there may be some discrepancies in the details provided. You might want to verify the details or check back later.",
  "84": "Here are some interventional studies for Breast Cancer that started in January 2007 in the United States obtained from ClinicalTrials.gov:\n\n1. [NCT00461773](https://clinicaltrials.gov/ct2/show/NCT00461773)\n2. [NCT02753673](https://clinicaltrials.gov/ct2/show/NCT02753673)\n3. [NCT00898573](https://clinicaltrials.gov/ct2/show/NCT00898573)\n4. [NCT00659373](https://clinicaltrials.gov/ct2/show/NCT00659373)\n5. [NCT01530373](https://clinicaltrials.gov/ct2/show/NCT01530373)\n6. [NCT05856773](https://clinicaltrials.gov/ct2/show/NCT05856773)\n7. [NCT03596073](https://clinicaltrials.gov/ct2/show/NCT03596073)\n8. [NCT05556473](https://clinicaltrials.gov/ct2/show/NCT05556473)\n9. [NCT02913573](https://clinicaltrials.gov/ct2/show/NCT02913573)\n10. [NCT03849573](https://clinicaltrials.gov/ct2/show/NCT03849573)\n\nPlease click on the links for more details about each study.",
  "85": "In the OpenTargets database for the event \"increased cardiac output\" concerning the target symbol GABRA5, the following information is available:\n\n- **Biosamples**:\n  - Central Nervous System (Tissue ID: UBERON_0001017)\n  - Cardiovascular System (Tissue ID: UBERON_0004535)\n\n- **Effects**:\n  - Dosing: Acute\n  - Direction: Activation/Increase/Upregulation",
  "86": "The following completed interventional studies in ClinicalTrials.gov investigated atrial fibrillation, stroke, or embolism with Rivaroxaban as an intervention in the United States, and started in December 2006:\n\n1. **Study NCT00403767**\n2. **Study NCT01747746**",
  "87": "Here are some interventional studies from ClinicalTrials.gov that focused on metastatic colorectal cancer with the interventions panitumumab and FOLFIRI, and started in June 2006 or later:\n\n1. [NCT03751176](https://clinicaltrials.gov/ct2/show/NCT03751176)\n2. [NCT06728072](https://clinicaltrials.gov/ct2/show/NCT06728072)\n3. [NCT02934529](https://clinicaltrials.gov/ct2/show/NCT02934529)\n4. [NCT01814501](https://clinicaltrials.gov/ct2/show/NCT01814501)\n5. [NCT03186326](https://clinicaltrials.gov/ct2/show/NCT03186326)\n6. [NCT06509126](https://clinicaltrials.gov/ct2/show/NCT06509126)\n7. [NCT00508404](https://clinicaltrials.gov/ct2/show/NCT00508404)\n8. [NCT02162563](https://clinicaltrials.gov/ct2/show/NCT02162563)\n9. [NCT04425239](https://clinicaltrials.gov/ct2/show/NCT04425239)\n10. [NCT03251612](https://clinicaltrials.gov/ct2/show/NCT03251612)\n\nPlease refer to the provided links for more details about each study.",
  "88": "[ERROR] 'NoneType' object is not subscriptable",
  "89": "For the target with Ensembl ID ENSG00000149295 and approved symbol DRD2, the following tractability information is available with a value of True:\n\n1. **Small Molecule (SM):**\n   - Approved Drug\n   - Structure with Ligand\n   - High-Quality Ligand\n   - Druggable Family\n\n2. **Antibody (AB):**\n   - UniProt location high confidence\n   - GO Cellular Component high confidence\n   - UniProt Signal Peptide or Transmembrane Helices\n\n3. **Protein (PR):**\n   - Small Molecule Binder\n\n4. **Other Categories (OC):**\n   - Approved Drug\n\nThese categorizations indicate the potential for developing therapeutic agents targeting DRD2 across various modalities such as small molecules, antibodies, and others.",
  "90": "The OpenTargets platform provides the following tractability information for the target with Ensembl ID ENSG00000169083 (approved symbol AR) where the value is True:\n\n1. **Small Molecule (SM)**\n   - Approved Drug\n   - Structure with Ligand\n   - High-Quality Ligand\n   - High-Quality Pocket\n   - Druggable Family\n\n2. **Antibody (AB)**\n   - GO Cellular Component (CC) high confidence\n\n3. **Protein (PR)**\n   - Advanced Clinical\n   - Literature\n   - UniProt Ubiquitination\n   - Database Ubiquitination\n   - Small Molecule Binder\n\nThese modalities indicate the different ways the target AR can be successfully targeted or modulated using drugs or other therapeutic approaches.",
  "91": "The target SSTR5 (Ensembl ID ENSG00000162009) is associated with the following diseases according to OpenTargets, with a minimum relevance score of 0.5:\n\n1. **IGF-1 measurement**\n   - Score: 0.6476\n\n2. **Acromegaly**\n   - Score: 0.6067\n\n3. **Neoplasm**\n   - Score: 0.5825\n\n4. **Neuroendocrine neoplasm**\n   - Score: 0.5489\n\n5. **Carcinoid tumor**\n   - Score: 0.5254",
  "92": "The PMID of the 2025 PLoS Medicine article titled “The cardiology community begins to embrace obesity as an important target for cardiovascular health,” authored by Sattar N, is 40273224.",
  "93": "The unique PMID for the article titled \"Home-based remote dance program with biopsychosocial model improves quality of life in breast cancer patients: A randomized controlled trial,\" authored by Yang YH, is 40483151.",
  "94": "In ClinicalTrials.gov, the interventional studies for hepatic encephalopathy with rifaximin or placebo that started in December 2005 include the following:\n\n1. NCT04073290\n2. NCT06538077\n\nThese are the studies that were actively recruiting during that time.",
  "95": "I found a completed interventional study for Beta-Thalassemia using LentiGlobin BB305 Drug Product that started in June 2017 in the United States. The NCT ID for this study is [NCT03207009](https://clinicaltrials.gov/ct2/show/NCT03207009).",
  "96": "Here are the interventional studies for hormone-refractory prostate cancer that started in May 2000 and used sipuleucel-T as a main intervention:\n\n1. [NCT01881867](https://clinicaltrials.gov/ct2/show/NCT01881867)\n2. [NCT01420965](https://clinicaltrials.gov/ct2/show/NCT01420965)\n3. [NCT01133704](https://clinicaltrials.gov/ct2/show/NCT01133704)\n4. [NCT01174368](https://clinicaltrials.gov/ct2/show/NCT01174368)\n5. [NCT02793765](https://clinicaltrials.gov/ct2/show/NCT02793765)\n6. [NCT01818986](https://clinicaltrials.gov/ct2/show/NCT01818986)\n7. [NCT01981122](https://clinicaltrials.gov/ct2/show/NCT01981122)\n8. [NCT01338012](https://clinicaltrials.gov/ct2/show/NCT01338012)\n9. [NCT01487863](https://clinicaltrials.gov/ct2/show/NCT01487863)\n10. [NCT03024216](https://clinicaltrials.gov/ct2/show/NCT03024216)\n11. [NCT05806814](https://clinicaltrials.gov/ct2/show/NCT05806814)\n12. [NCT02159950](https://clinicaltrials.gov/ct2/show/NCT02159950)\n13. [NCT01560923](https://clinicaltrials.gov/ct2/show/NCT01560923)\n14. [NCT02036918](https://clinicaltrials.gov/ct2/show/NCT02036918)\n15. [NCT03329742](https://clinicaltrials.gov/ct2/show/NCT03329742)\n16. [NCT02793219](https://clinicaltrials.gov/ct2/show/NCT02793219)\n17. [NCT00901342](https://clinicaltrials.gov/ct2/show/NCT00901342)\n18. [NCT01832870](https://clinicaltrials.gov/ct2/show/NCT01832870)\n19. [NCT00065442](https://clinicaltrials.gov/ct2/show/NCT00065442)\n20. [NCT02237170](https://clinicaltrials.gov/ct2/show/NCT02237170)\n21. [NCT01477749](https://clinicaltrials.gov/ct2/show/NCT01477749)\n22. [NCT02463799](https://clinicaltrials.gov/ct2/show/NCT02463799)\n23. [NCT02353715](https://clinicaltrials.gov/ct2/show/NCT02353715)\n24. [NCT06134232](https://clinicaltrials.gov/ct2/show/NCT06134232)\n25. [NCT06100705](https://clinicaltrials.gov/ct2/show/NCT06100705)\n26. [NCT02042053](https://clinicaltrials.gov/ct2/show/NCT02042053) \n\nYou can click on each link to get detailed information about the respective study.",
  "97": "The PMID of the article titled \"Revolutionizing pediatric neurology care: telemedicine advancements and regulatory impact in the Northeast of Brazil,\" authored by Rodrigues DLG and published in Arquivos de Neuro-Psiquiatria in 2025, is 40262814.",
  "98": "The PMID of the article titled “A rare case of rectal malignant melanoma with long-term survival: case report and literature review,” authored by Huang H and published in the World Journal of Surgical Oncology in 2025 is 40483466.",
  "99": "The PMID of the article titled \"Impact of the COVID-19 pandemic on the diagnosis, tumor characteristics, and survival outcomes of colorectal cancer: a retrospective cohort study,\" authored by Yarikkaya E and published in Annals of Saudi Medicine in 2025, is 40482190."
}